Savara (SVRA) Prices Public Offering of Common Stock, Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Oppenheimer Starts Savara (SVRA) at Outperform
March 15, 2021 5:46 AM EDTOppenheimer analyst Francois Brisebois initiates coverage on Savara (NASDAQ: SVRA) with a Outperform rating and a price target of $4.00.
The analyst comments "Savara (SVRA) has recently simplified the company to focus solely on its main value driver, molgramostim nebulizer solution (molgramostim) for Autoimmune Pulmonary... More
Savara (SVRA) Stock Offering is Said to Price at $1.45 Per Share - Bloomberg
March 11, 2021 8:56 AM ESTSavara (NASDAQ: SVRA) Stock Offering is Said to Price at $1.45 Per Share - Bloomberg
Savara (SVRA) Announces Proposed Public Offering of Common Stock
March 10, 2021 4:49 PM ESTSavara Inc. (Nasdaq:... More
